Esomeprazole With Aspirin Versus Clopidogrel for Prevention of Recurrent Gastrointestinal Ulcer Complications

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 7, 2006, Pages 860-865

  Lai, Kam Chuen ^a   Chu, Kent Man ^a   Hui, Wai Mo ^a   Wong, Benjamin Chun Yu ^a   Hung, Wai Ka ^b   Loo, Ching Kong ^b   Hu, Wayne Hsing Ching ^a   Chan, Annie On On ^a   Kwok, Ka Fai ^a   Fung, Tang Tat ^b   Wong, John ^a   Lam, Shiu Kum ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DYSPEPSIA; FEMALE; FOLLOW UP; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LOG RANK TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE;

AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ASPIRIN; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STOMACH ULCER; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33745610044     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.04.019     Document Type: Article

References (16)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
2. Weisman S.M., and Graham D.Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162 (2002) 2197-2202
3. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
4. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
6. ACC/AHA. 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available: http://www.acc.org/clinical/guidelines/unstable/III_hospital.htm#III_B1.
7. Fork F.T., Lafolie P., Toth E., et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 35 (2000) 464-469
8. Ng F.H., Wong S.Y., Chang C.M., et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 18 (2003) 443-449
9. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
10. Hui W.M., Lam S.K., Ho J., et al. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci 36 (1991) 577-582
11. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
12. Patrono C., Coller B., Fitzgerald G.A., et al. Platelet-active drugs. the relationships among dose, effectiveness, and side effects. Chest 126 Suppl (2004) 234S-264S
13. Hawkey C.J., Laine L., Harper S.E., et al., Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 15 (2001) 1593-1601
14. Hawkey C.J., and Langman M.J. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52 (2003) 600-608
15. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other non-steroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
16. Ng F.H., Wong B.C., Wong S.Y., et al. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk-a single-blind, randomized controlled study. Aliment Pharmacol Ther 19 (2004) 359-365